TrialOral oncology2018

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

Robert L Ferris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.